(Total Views: 1028)
Posted On: 10/01/2020 10:17:44 AM
Post# of 151796
Some hard cold reality is setting in today. All of the short term backstops to support the $3 price are gone. It's interim CD12 or bust for 2020.
Discussions with Big Pharma...give me a break. I heard this every call since I bought in Q1 of 2018, and it's a joke. I can't say it's an outright lie, but there isn't anyone out there ready to cut a deal with Cytodyn for either a buyout or licensing opportunities. 0-25 in three years, and 25 may be low for the number of mentions.
NASDAQ DOA.
BLA by "EOY". I heard that about the same time last year.
Longhaulers is a waste of time.
P3 CD10 will be in line behind other products before completed.
Full enrollment on CD12 is 4-6 months from having data we could use.
So where are we on CD12? The high number of deaths gives us a chance to show statistical significance beyond a shadow of a doubt and mandate that they halt the trial and give us EUA...on the other hand, the high number of deaths could mean we aren't working as well as we hoped.
Discussions with Big Pharma...give me a break. I heard this every call since I bought in Q1 of 2018, and it's a joke. I can't say it's an outright lie, but there isn't anyone out there ready to cut a deal with Cytodyn for either a buyout or licensing opportunities. 0-25 in three years, and 25 may be low for the number of mentions.
NASDAQ DOA.
BLA by "EOY". I heard that about the same time last year.
Longhaulers is a waste of time.
P3 CD10 will be in line behind other products before completed.
Full enrollment on CD12 is 4-6 months from having data we could use.
So where are we on CD12? The high number of deaths gives us a chance to show statistical significance beyond a shadow of a doubt and mandate that they halt the trial and give us EUA...on the other hand, the high number of deaths could mean we aren't working as well as we hoped.
(15)
(9)Scroll down for more posts ▼
